Clinical Trials Browser

Phase 1/2 × Uveal Melanoma × Solutions × Clear all

NCT06784648 2025-11-19

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

Phase 1/2 Active not recruiting

Uveal Melanoma, Melanoma, Neoplasm Metastasis